Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Depreciation and Depletion (2018 - 2025)

BioNexus Gene Lab's Depreciation and Depletion history spans 8 years, with the latest figure at $29001.0 for Q3 2025.

  • For Q3 2025, Depreciation and Depletion fell 15.37% year-over-year to $29001.0; the TTM value through Sep 2025 reached $28970.0, down 69.41%, while the annual FY2024 figure was $20138.0, 75.81% down from the prior year.
  • Depreciation and Depletion for Q3 2025 was $29001.0 at BioNexus Gene Lab, up from $27800.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $63129.0 in Q3 2023 and bottomed at -$54473.0 in Q4 2024.
  • The 5-year median for Depreciation and Depletion is $22466.0 (2021), against an average of $19449.6.
  • The largest annual shift saw Depreciation and Depletion surged 254.67% in 2021 before it tumbled 370.93% in 2024.
  • A 5-year view of Depreciation and Depletion shows it stood at $22794.0 in 2021, then grew by 8.88% to $24819.0 in 2022, then decreased by 18.99% to $20106.0 in 2023, then crashed by 370.93% to -$54473.0 in 2024, then surged by 153.24% to $29001.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Depreciation and Depletion are $29001.0 (Q3 2025), $27800.0 (Q2 2025), and $26642.0 (Q1 2025).